Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients.

ABSTRACT: Multiple myeloma (MM) is an incurable plasma cell hematological malignancy. Bortezomib has become the primary drug in the treatment of patients with MM. However, its negative effects, especially peripheral neuropathy (PN), affect the patients' life quality and treatment continuity. However, there are few studies on baseline PN of MM, and little is known of the impact of baseline PN on the prognosis of MM patients. Therefore, we reviewed the clinical data of newly diagnosed MM patients in our center, explored the influencing factors of baseline PN, and evaluated PN's influence on the prognosis of MM patients undergoing induction therapy with bortezomib. According to the inclusion and exclusion criteria, 155 MM patients were eligible for the retrospective study. The multivariate regression a

SUBMITTER: Dong M 

PROVIDER: S-EPMC9203796 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature